Warner Chilcott has been cleared by the Food and Drug Administration to market 200-mg strength of Doryx delayed-release tablets.


Warner Chilcott, Doryx, Food and Drug Administration, doxycycline hyclate, oral antibiotic








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Warner Chilcott receives FDA approval for Doryx tablets

April 15th, 2013

DUBLIN, Ireland – Warner Chilcott has been cleared by the Food and Drug Administration to market 200-mg strength of Doryx delayed-release tablets.

The Ireland-based pharmaceutical company said Friday that it expects the commercial launch of the Doryx tablets to take place in July.

A tetracycline-class oral antibiotic, Doryx (doxycycline hyclate) is used to treat a range of bacterial infections, such as urinary tract infections, acne, gonorrhea, chlamydia, periodontitis. It's also used to treat blemishes, bumps and acne-like lesions caused by rosacea.

Advertisement